Literature DB >> 15888750

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma.

J-L Harrouseau1, R Greil, O Kloke.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15888750     DOI： 10.1093/annonc/mdi818

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

Review 1.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

2.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Authors:  Evangelos Terpos; Gareth Morgan; Meletios A Dimopoulos; Matthew T Drake; Suzanne Lentzsch; Noopur Raje; Orhan Sezer; Ramón García-Sanz; Kazuyuki Shimizu; Ingemar Turesson; Tony Reiman; Artur Jurczyszyn; Giampaolo Merlini; Andrew Spencer; Xavier Leleu; Michele Cavo; Nikhil Munshi; S Vincent Rajkumar; Brian G M Durie; G David Roodman
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

Review 3.  Cancer-associated bone disease.

Authors:  R Rizzoli; J-J Body; M-L Brandi; J Cannata-Andia; D Chappard; A El Maghraoui; C C Glüer; D Kendler; N Napoli; A Papaioannou; D D Pierroz; M Rahme; C H Van Poznak; T J de Villiers; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-10-22       Impact factor: 4.507

Review 4.  Prevention and treatment of myeloma bone disease.

Authors:  Evangelos Terpos; Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

5.  Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.

Authors:  Kari Remes; Pekka Anttila; Raija Silvennoinen; Mervi Putkonen; Hanna Ollikainen; Venla Terävä; Marjatta Sinisalo; Kristiina Kananen; Frida Schain; Päivi Castren-Kortegangas; Tiina M Järvinen; Marta Pisini; Felix Wahl; Tricia Dixon; Amy Leval
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

6.  Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia.

Authors:  Susanne Knoll; Sabiene Zimmer; Anke Hinney; André Scherag; Andreas Neubauer; Johannes Hebebrand
Journal:  BMC Cancer       Date:  2008-03-31       Impact factor: 4.430

7.  The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.

Authors:  T Lebret; A Casas; M Cavo; P J Woll; C Deleplace; C Kennedy; P Schoen; C Jackisch
Journal:  Eur J Cancer Care (Engl)       Date:  2016-04-12       Impact factor: 2.520
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.